That day, the Twitter account @EliLillyandCo posted ... Eli Lilly accounts had issued their fake insulin tweets, Eli Lilly’s stock share price tumbled by 4.37% or $16.08 down to $352.30 ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

I think the stock is a good pick to buy with the recent pullback. Forget last week's Twitter tumult. Lilly is a verified winner. 10 stocks we like better than Eli Lilly and Company When our award ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Insulin producer Eli Lilly faces the economic ... producer saw a 4.5 percent drop in its stock and had to issue a clarification on its official Twitter account, @LillyPad. Mashable Trend Report ...

Billionaire Elon Musk’s changes to social media giant Twitter are already costing some companies billions in total stock value. Pharmaceutical company Eli Lilly (LLY) dipped 4.37 per cent Friday ...

Pharma company Eli Lilly has been criticized heavily in the past for the price of insulin, but the company has claimed it is not profiting off those increases. Photo: Darron Cummings (AP) As much ...

Eli Lilly & Co. investors were having their best day in more than two decades on Tuesday, after the drug giant reported second-quarter earnings that beat expectations, and after favorable trial ...

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

And if those prospects are strong, it wouldn't be surprising to see the healthcare stock take off on the developments. Eli Lilly stock could prove to be a no-brainer buy right now It has been a ...

But is Eli Lilly stock a buy after last week's Twitter prank? A Twitter account calling itself "Eli Lilly and Company" tweeted on Thursday, Nov. 10, 2022, "We are excited to announce insulin is ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.